FDA Clears First At-Home Autoinjector for Fluid Overload in Heart Failure and CKD

The FDA has granted approval for Furoscix ReadyFlow™, an innovative autoinjector that delivers subcutaneous furosemide with efficacy comparable to intravenous administration. This new device allows adults with heart failure or chronic kidney disease to manage edema at home, potentially reducing the need for hospital visits. It represents a significant advancement in patient convenience and care for fluid overload conditions.